When does the Entyvio patent expire?
Entyvio (vedolizumab) is protected by a web of intellectual-property rights, including patents covering the drug substance and formulations. The exact “patent expiry date” depends on which specific patent is being considered (and which country), because different patents can expire on different schedules.
To identify the controlling patents and their likely expiry timelines, DrugPatentWatch.com tracks vedolizumab patent filings and exclusivity-related events. See: DrugPatentWatch – Entyvio (vedolizumab).
Which patents matter most for generic or biosimilar entry?
For biologics like Entyvio, entry is usually delayed not by a single patent but by overlapping protections. The most relevant are typically:
- Patents tied to the active ingredient (vedolizumab)
- Patents tied to manufacturing/process
- Patents tied to specific formulations or variants
- Patent “family” members that may expire later in some jurisdictions
Those are the types of rights you can map using the patent lists and expiry estimates shown on DrugPatentWatch.com. [1]
Are there biosimilars for Entyvio already, or will they wait for patent expiry?
Because Entyvio is a monoclonal antibody, potential competitors are generally biosimilars rather than small-molecule generics. Whether a biosimilar can launch depends on:
- Regulatory approval pathway (biosimilar/biologic license)
- Patent and exclusivity status in the target market
- Any ongoing patent disputes (if a biosimilar challenges listed patents)
Patent expiry timing is therefore a major driver of biosimilar launch dates, but it does not always line up perfectly with “the end date” of the first patent you see. Patent-family coverage can push launch later. [1]
Why does “Entyvio patent expiry” differ by country?
Patent rights and regulatory exclusivities are country-specific. The same biologic can have:
- Different patent filing dates and grant dates by jurisdiction
- Different claim scope
- Different regulatory exclusivity rules (which can extend effective market protection beyond the earliest patent expiry)
So a single global expiry date is usually not accurate. You need to check the market you care about (for example, the U.S. versus EU/UK) and the specific patents listed for that territory. [1]
How to check the exact Entyvio patents (and their expiry estimates)
If your goal is to find the specific patent numbers and the estimated end dates, use the inventor/patent timeline view on DrugPatentWatch.com for vedolizumab/Entyvio. It’s the most practical way to connect the drug name to the patent families and expiry windows. [1]
Sources:
1. DrugPatentWatch – Entyvio (vedolizumab)